From Brain to Blood: Uncovering Potential Therapeutical Targets and Biomarkers for Huntington's Disease Using an...

Area of Science:

• Genomics
• Neuroscience
• Biomarker Discovery

Background:

• Huntington's Disease (HD) currently lacks disease-modifying treatments, with therapies focusing on symptom management.
• Existing treatments for HD offer limited efficacy, highlighting the urgent need for novel therapeutic strategies.
• Identifying druggable genes and reliable biomarkers is crucial for advancing HD research and treatment.

Purpose of the Study:

• To identify potential therapeutic targets and biomarkers for Huntington's Disease (HD).
• To leverage RNA-Seq analysis for uncovering molecular targets in HD.
• To enhance the outcomes of future clinical trials for HD.

Main Methods:

• Reanalysis of transcriptomic data from six independent studies comparing HD patients and healthy controls.
• Application of Propensity Score Matching (PSM) to control for age differences between cases and controls.
• Utilizing differential expression analysis (DEA) and machine learning to identify differentially expressed genes (DEGs) and biomarkers in HD.

Main Results:

• Identification of 5834 DEGs, including 394 putative druggable genes implicated in neuroinflammation, metal ion dysregulation, and blood-brain barrier dysfunction.
• Correlation of gene expression levels with CAG repeat length, disease onset, and progression in HD patients.
• Discovery of FTH1 as a potential HD biomarker, showing downregulation in the prefrontal cortex and upregulation in peripheral blood, dependent on CAG repeat length.

Conclusions:

• FTH1 demonstrates potential as both a diagnostic biomarker and a therapeutic target for Huntington's Disease.
• Advanced bioinformatics approaches, including RNA-Seq and PSM, are vital for discovering novel therapeutic targets in HD.
• Further research is necessary to validate the role of FTH1 and its therapeutic utility in managing HD.